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Abstract:  A series of α-alkyl-α-amino-β-sulphone hydroxamates was prepared and evaluated for potency 
versus MMP-2 and MMP-13, and for selectivity versus MMP-1. Low nanomolar potency was obtained with 
selectivity versus MMP-1 ranging from >10 to >1,000.  Selected compounds were orally bioavailable. 
 
Introduction 
In our previous letter we descirbed a series of α-amino-β-sulphone hydroxamates which are potent inhibitors of 
MMP-13 which spare MMP-1.1  Overexpressed MMPs play a crucial role in tumor growth and metastasis in 
cancer, and in the destruction of articular cartilage in osteoarthritis (OA) and rheumatoid arthritis (RA).  Hence, 
the inhibition of the relevant MMP enzymes may prove to be clinically effective in halting the advance of these 
diseases.2  The gelatinases A and B (MMP-2 and MMP-9) have been implicated in tumor progression,3  and 
MMP-13 has been implicated in the destruction of articular cartilage in arthritis.4  Herein we report the 
preparation and preliminary SAR of a series of α-amino-α-alkyl-β-sulphones which are highly selective in 
sparing MMP-1, based on the hypothesis that the musculoskeletal side effect observed clinically with the 
broad-spectrum inhibitor marimastat5 is due to potent inhibition of MMP-1. Alkyl substituents alpha to the 
hydroxamate were employed to modulate pharmacokinetic properties including absorption and half-life, as 
well as physicochemical properties, while the P1' substituent was varied to optimize potency and selectivity. 
Chemistry 
The targeted α-methyl-α-amino diphenyl ether hydroxamates of type 5 were prepared starting with a halide 
displacement of chloroacetone (1) with 4-phenoxythiophenol6 to afford 2 (Scheme 1).   Strecker synthesis then 
gave the nitrile 3 which was hydrolyzed to the carboxylic acid.  Oxidation of the sulfide after protection of the 
amino group as the acetamide, and subsequent deprotection then gave the amino acid 4.  Functionalization of 
the amino group was accomplished by alkylation, acylation or reductive amination as required, and standard 
EDC coupling with hydroxylamine afforded the diphenyl ether sulphone hydroxamates 5. 
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The diaryl thioether 7 was prepared by reacting chloroacetone (1) with 4-fluorothiophenol (R = F).  Strecker 
synthesis gave nitrile 3 (R = F) which was hydrolyzed and protected as the acetamide (Scheme 2).  Oxidation 
then afforded the corresponding 4-fluorophenylsulphone, and nucleophilic aromatic substitution with 
thiophenol gave carboxylic acid 6.  Acetamide hydrolysis preceded amino functionalization with the 
appropriate R2 reagent, and EDC coupling afforded the hydroxamates 7.   
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As illustrated in Scheme 3, α-pyrrolidine-β-sulphones were prepared from racemic methyl N-Cbz-proline (8).  
Alkylation7 with methylene diiodide gave the α-iodomethyl derivative which was used to alkylate 4-
phenoxythiophenol, and oxidation gave the sulphone 9.  The Cbz protecting group was removed by 
hydrogenolysis, exposing the amine which was functionalized by alkylation with propargyl bromide.  
Saponification of the methyl ester and coupling with hydroxylamine then afforded the hydroxamate 10 (R2 = 
propargyl).   
Scheme 3 
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The α-phenyl-α-amino derivative 15 (Scheme 4) was prepared from D,L-phenylglycine (11) by benzoylation 
and treatment with acetic anhydride to give the 2-phenyloxazolone 128 (Scheme 4).  Alkylation of this 
azlactone with methylene diiodide gave iodomethyl azlactone 13, and displacement of the iodide with 4-
phenoxythiophenol and subsequent oxidation with metachloroperbenzoic acid gave the sulphone 14.  The 
oxazolone was then hydrolyzed and the resulting carboxylic acid coupled with TMS-protected hydroxylamine 
to afford 15 (R2 = H).  Alternatively, the oxazolone ring was opened directly with hydroxylamine to afford the 
benzamide hydroxamate (R2 = Bz). 
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Results and Discussion 
Table 1 summarizes the potency versus MMP-2, MMP-13 and MMP-1 for compounds of generic structures 5, 
7 and 15.  The diaryl ethers (X = O) were an order of magnitude more potent than the corresponding thioethers 
(X = S), although the thioethers were noted to be somewhat more selective in sparing MMP-1 (5a and 5b 
versus 7a and 7b).  Amides of the α-amino group (compounds 5a, 5j, 7a and 15a) were not well tolerated, 
whereas simple alkyl and aralkyl amines were potent for both MMP-2 and MMP-13.  Disubstitution on the 
amine led to a loss of potency (5c).  The α-phenyl amine 15b was potent for MMP-13 and MMP-2, but was 
also somewhat more potent for MMP-1.  Almost all compounds exhibited excellent selectivity versus MMP-1, 
in several cases exceeding 1000X for the ratio of IC50 values (MMP-1/MMP-2 and MMP-1/MMP-13), in 
contrast to the broad-spectrum inhibitors CGS 27023A and marimastat. 
 
Table 2 shows the enzyme potency of proline-derived analog 10.  Since the racemate 10 was found to be quite 
potent, the material was resolved into its enantiomers via chiral chromatography.9  The first eluter, 
hydroxamate 10a, was found to be the more potent enantiomer (eutomer) by at least two orders of magnitude 
against both MMP-13 and MMP-2 as compared to the less potent enantiomer (distomer) 10b.  Compound 10a 
was also highly selective in sparing MMP-1 (3000X). 
 
 
 
 
 
Table 1: IC50 (nM)10 values for α-alkyl-α-amino-β-sulphone hydroxamates 
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Compound R1 R2 R3 X MMP-13 MMP-2 MMP-1 
5a CH3 Ac H O 41.5 40.0 >10,000 
5b CH3 H H O 0.2 0.6 170 
5c CH3 CH3 CH3 O 24.0 5.0 >10,000 
5d CH3 CH2CH3 H O 1.6 1.3 1600 
5e CH3 CH2Ph H O 0.3 0.2 1200 
5f CH3 CH2CH2Ph H O 2.4 1.3 2400 
5g CH3 3,4-methylenedioxybenzyl H O 1.1 0.5 2350 
5h CH3 2-naphthylmethyl H O 1.4 0.4 >10,000 
5i CH3 propargyl H O 0.6 0.2 700 
5j CH3 pyrrolidineacetyl H O 160 80 >10,000 
7a CH3 Ac H S 580 540 >10,000 
7b CH3 H H S 2.4 3.2 4400 
15a Ph benzoyl H O 161 184 >10,000 
15b Ph H H O 0.4 0.2 130 
CGS 27023A     5.1 4.6 34.3 
marimastat     2.0 0.75 2.9 
 
Table 2: IC50 (nM)10 values for α-pyrrolidine-β-sulphone hydroxamates 
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Compound R2 MMP-13 MMP-2 MMP-1 
10 (racemic) propargyl 1.3 0.2 400 
10a (eutomer) propargyl <0.1 <0.1 300 
10b (distomer) propargyl 60.0 19.3 >10,000 
 
Selected analogs were dosed orally in rats at 20 mpk to assess absorption by measuring C
max
, and the 
concentration remaining at 6 hours was used as an initial rough indicator of the half-life.  The α-methyl-α-
amino analog 5b showed a high C
max
 of 6.43 ug/ml, somewhat greater than the corresponding thioether 7b (C
max
 
= 1.54 ug/ml).  N-ethyl and N-benzyl analogs 5d and 5e were moderately well absorbed (C
max
 = 0.561 and 
0.216 ug/ml, respectively), and N-propargyl amine 5i exhibited a Cmax of 1.37 ug/ml.  However, all of the 
compounds tested were less than 15 ug/ml in plasma at the 6 h time point. 
In summary, we have described a promising series of α-alkyl-α-amino-β-sulphone hydroxamates which are 
potent inhibitors of both MMP-2 and MMP-13, and which spare MMP-1.  Several analogs showed good 
absorption when administered orally in the rat.  The efficacy of these compounds in animal models of cancer 
and arthritis will be disclosed in due course. 
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